James Edgemond sold $2.9M of UTHR
CFO AND TREASURER at UNITED THERAPEUTICS Corp. 7,778 shares at an average of $374.02, traded Nov 4, 2024, filed Nov 5, 2024.
Score components
- +22RoleCFO
- +25Trade size$2.9M at market
- +20Share of holdings soldSold 72% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -2.2%, 3m -7.7%, 6m -22.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-026147, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 4, 2024 | MOption exercise Common Stock10b5-1 | +3,267 | $120.26 | $393k | 10,779 | Nov 5, 2024 |
| Nov 4, 2024 | SOpen-market sale Common Stock10b5-1 | -3,267 | $374.02 | $1.2M | 7,512 | Nov 5, 2024 |
| Nov 4, 2024 | MOption exercise Common Stock10b5-1 | +3,400 | $117.76 | $400k | 10,912 | Nov 5, 2024 |
| Nov 4, 2024 | SOpen-market sale Common Stock10b5-1 | -3,400 | $374.02 | $1.3M | 7,512 | Nov 5, 2024 |
| Nov 4, 2024 | MOption exercise Common Stock10b5-1 | +817 | $120.26 | $98k | 8,329 | Nov 5, 2024 |
| Nov 4, 2024 | SOpen-market sale Common Stock10b5-1 | -546 | $374.02 | $204k | 7,783 | Nov 5, 2024 |
| Nov 4, 2024 | MOption exercise Common Stock10b5-1 | +850 | $117.76 | $100k | 8,633 | Nov 5, 2024 |
| Nov 4, 2024 | SOpen-market sale Common Stock10b5-1 | -565 | $374.02 | $211k | 8,068 | Nov 5, 2024 |
| Nov 4, 2024 | MOption exercise Stock Optionsderivative10b5-1 | -3,267 | $0.00 | $0 | 817 | Nov 5, 2024 |
| Nov 4, 2024 | MOption exercise Stock Optionsderivative10b5-1 | -3,400 | $0.00 | $0 | 112,350 | Nov 5, 2024 |
| Nov 4, 2024 | MOption exercise Stock Optionsderivative10b5-1 | -817 | $0.00 | $0 | 0 | Nov 5, 2024 |
| Nov 4, 2024 | MOption exercise Stock Optionsderivative10b5-1 | -850 | $0.00 | $0 | 111,500 | Nov 5, 2024 |
Related signals
Other insiders at UNITED THERAPEUTICS Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.5M 9,500 shares | -3% | |
| 18Weak | UNITED THERAPEUTICS Corp | Paul A Mahon EVP & GENERAL COUNSEL | $4.7M 8,300 shares | -16% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $3.9M 7,580 shares | -2% | |
| 38Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $1.1M 1,920 shares | -1% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $4.5M 9,500 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.